Literature DB >> 1395348

Reverse crossed cerebellar diaschisis in partial complex seizures related to herpes simplex encephalitis.

C H Park1, S M Kim, L J Streletz, J Zhang, C Intenzo.   

Abstract

Tc-99m HMPAO brain SPECT was performed in a patient who had partial complex seizures for 1 year after successful acyclovir treatment of biopsy-proven herpes simplex encephalitis 2 years earlier. In spite of antiepileptic medications, her seizures were intractable and occurred daily. Tc-99m HMPAO was administered intravenously while she was having subclinical seizures, and brain SPECT demonstrated an area of hyperperfusion in the right temporal lobe medially and in the contralateral cerebellum. This reverse of the crossed cerebellar diaschisis phenomenon in epileptic disorders has not previously been documented.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1395348     DOI: 10.1097/00003072-199209000-00011

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

1.  Crossed cerebellar diaschisis in acute ischemic stroke: Impact on morphologic and functional outcome.

Authors:  Wolfgang G Kunz; Wieland H Sommer; Christopher Höhne; Matthias P Fabritius; Felix Schuler; Franziska Dorn; Ahmed E Othman; Felix G Meinel; Louisa von Baumgarten; Maximilian F Reiser; Birgit Ertl-Wagner; Kolja M Thierfelder
Journal:  J Cereb Blood Flow Metab       Date:  2017-01-13       Impact factor: 6.200

2.  Significance of postoperative crossed cerebellar hypoperfusion in patients with cerebral hyperperfusion following carotid endarterectomy: SPECT study.

Authors:  Kuniaki Ogasawara; Masakazu Kobayashi; Yasunori Suga; Kohei Chida; Hideo Saito; Nobukazu Komoribayashi; Yasunari Otawara; Akira Ogawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-26       Impact factor: 9.236

3.  Crossed Cerebellar Diaschisis: Three Case Reports Imaging Using a Tri-Modality PET/CT-MR System.

Authors:  Shuguang Han; Xiaopeng Wang; Kai Xu; Chunfeng Hu
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.